Median overall survival was 11.4 months in patients receiving immunotherapy alone, which is approximately 15 months less than reported in a previous clinical study. The adjusted limited mean survival time to 18 months of follow-up was 11-13 months for all treatment groups, including those receiving chemotherapy alone.
“These results, based on the nationwide experience of patients with Medicare, may inform discussions between physicians and patients regarding expectations for outcomes in elderly patients with non-small cell lung cancer,” said Kenneth L. Kehl, MD, assistant professor of MPH. of Medicine at Harvard Medical School and the study’s lead author. He noted that “the shorter survival times observed in the Medicare population may reflect the treatment of elderly patients with higher burden of frailty and comorbidities.”
Deborah Schrag, MD, MPH, the study’s senior author and head of the Population Sciences division at Dana-Farber and Harvard Medical School noted “This information empowers patients and clinicians with realistic expectations and equips them to make informed decisions. Evaluation of Medicare claim data is an appropriate approach for measuring real-world outcomes.”
“Immunotherapy holds great promise as a relatively new treatment option,” said Nassib Chamoun, CEO and founder of HDAI. That said, it is important to understand how well the results of carefully controlled studies generalize to the more vulnerable Medicare population in order to optimize treatment choice and allow for informed treatment discussions. biomarkers and markers of co-morbidity in the evolution of personalized care for lung cancer patients. “
About the Dana-Farber Cancer Institute:
Cancer Institute Dana-Farber is one of the world’s leading centers for cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific research, clinical care, education, community involvement and advocacy. We offer the latest cancer treatments for adults throughout Dana-Farber / Brigham and Women’s Cancer Center and for children through Dana-Farber / Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the only nationwide hospital with a top 6 US News & World Report Best Cancer Hospital in both Adult and Pediatric Care.
As a world leader in oncology, Dana-Farber is committed to a unique and equal balance of cancer research and care, translating the results of discoveries into new treatments for patients locally and around the world, with more than 1,100 clinical trials.
Health Data Analytics Institute (HDAI) is an analysis company with a validated, predictive platform for measuring health risks in the short and long term. The HDAI suite of predictive models is based on research with more than 20 years of claim data, hundreds of millions of claim records and collaboration with academic and industry research partners. It has developed a Risk Stratification Index (RSI) score that serves as a composite measure of the mortality risk associated with underlying medical conditions. Progressive health systems, physician groups and life science companies are applying HDAI’s solutions to support the development of effective and targeted care plans, the delivery of higher quality patient care and the delivery of appropriate services for the population. For more information, please visit: www.hda-institute.com
for Health Data Analytics Institute
SOURCE Health Data Analytics Institute